FDA issues final guidance for psychedelic drug developers and announces public hearing
read at Endpoints ↗RegulatoryPositive
The FDA has completed a set of clinical guidance documents aimed at companies developing psychedelic medicines.
The guidance outlines expectations for trial design, safety monitoring, and data collection to support future regulatory submissions.
The agency also scheduled a public hearing to discuss the therapeutic potential and regulatory pathway for psychedelics, signaling increased regulatory focus.
Industry observers view the step as adding momentum to a field that is approaching possible approvals.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “FDA finalizes guidance on psychedelics, plans broader hearing”
read at Endpoints ↗79 words · retrieved Jul 13
comments(0)
5-min edit window · permanent after that